SCHEMBL2208602

SCHEMBL2208602

CC1(C)CC2(CC(C)(C)N1)NC(=O)N(CCS(=O)(=O)O)C2=O

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 3/20 0.38
TACR1 P25103 1/20 0.31
POLB P06746 2/20 0.31
RAB9A P51151 2/20 0.31
ALOX15 P16050 1/20 0.31
RECQL P46063 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KMT2A Q03164 2/20 0.31
MAPT P10636 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11593495 0.82 LMNA (0.36) ALDH1A1LMNATACR1POLBRAB9A
SCHEMBL11353453 0.80 CNR1 (0.43) ALDH1A1LMNATACR1MAPTSMN1; SMN2
SCHEMBL11761589 0.79 CNR1 (0.46) ALDH1A1LMNATACR1RAB9AL3MBTL1
SCHEMBL3243759 0.79 LMNA (0.36) ALDH1A1LMNAPOLBKMT2AMAPT
SCHEMBL11153550 0.79 CNR1 (0.48) ALDH1A1KDM4ELMNATACR1RAB9A
SCHEMBL11765260 0.78 CNR1 (0.42) ALDH1A1KDM4ELMNATACR1RAB9A
SCHEMBL11763084 0.78 ALDH1A1 (0.47) ALDH1A1LMNAALOX15MAPTSMN1; SMN2
SCHEMBL3245578 0.77 POLB (0.55) ALDH1A1LMNAPOLBALOX15KMT2A
SCHEMBL2893463 0.77 CNR1 (0.50) ALDH1A1TACR1RAB9ASMN1; SMN2
SCHEMBL5584007 0.77 CNR1 (0.50) ALDH1A1TACR1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
EP-2341777-B1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-01-21 EP disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
US-8722715-B2 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions NovaBay Pharmaceuticals (US) 2014-05-13 US disclosed
EP-2341777-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NovaBay Pharmaceuticals, Inc. (US) 2011-07-13 EP disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-03 US disclosed
WO-2010054009-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed
WO-2010054009-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137349-A1 ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS OXA1L, NISCH, ODC1 ALDH1A1 1885/4885KDM4E 2928/4885LMNA 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.